Third party review proves unpopular in US
This article was originally published in Clinica
Executive Summary
The US FDA is disappointed by the poor response to its third party review pilot programme. The two-year programme is testing whether review times will improve if private organisations are used to evaluate 510(k) applications for low and moderate risk products which require no clinical data on safety and effectiveness.